John Kuruvilla

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Michael Crump, Sattva S. Neelapu, Umar Farooq et al. · Blood · 2017 · 1.6K citations · Full text

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

Anas Younes, Armando Santoro, Margaret A. Shipp et al. · The Lancet Oncology · 2016 · 915 citations · Full text

Lymphoid Neoplasia, Transplantation, Marrow Transplantation +13

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

Philippe Armand, Andreas Engert, Anas Younes et al. · Journal of Clinical Oncology · 2018 · 734 citations · Full text

Cell Therapy, Relapsed/refractory Chl, Immunology +16

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

Philippe Armand, Margaret A. Shipp, Vincent Ribrag et al. · Journal of Clinical Oncology · 2016 · 667 citations · Full text

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

Nathalie A. Johnson, Kerry J. Savage, Olga Ludkovski et al. · Blood · 2009 · 579 citations · Full text